At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,000 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genetic and Environmental Pathogenesis of PPH
In Brief
An observational study for Lung Diseases and Hypertension, Pulmonary. Completed, enrolled 3,000 participants across 1 site.
Detailed Summary
The goal of this study is to identify the modifying genes and environmental features that regulate the clinical expression of mutations in bone morphogenetic protein receptor 2 (BMPR2); to develop the understanding of how BMPR2 mutations result in disease; and to identify the undiscovered genetic mutations that cause primary pulmonary hypertension (PPH).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Diseases, Hypertension, Pulmonary
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2003
First PostedSep 2004
Primary CompletionJul 2009
TodayJul 2026
First PostedSep 13, 2004
Enrollment StartAug 1, 2003
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 21.8 years ago